Testing for Pancreatic Cancer
March 7, 2022
Introducing the IMMray® PanCan-d test
Pancreatic cancer is often viewed as a death sentence, primarily because the majority of patients are diagnosed with late-stage disease when surgery is not possible. But if you can detect it early, in stage I or even II, the five-year survival rate improves drastically.
Immunovia’s mission is to improve early detection rates of pancreatic cancer to allow for more and better treatment options. By educating individuals and primary care practitioners about the IMMray® PanCan-d test, they hope to achieve their goal.
The IMMray® PanCan-d test is the first and only blood test dedicated to the early detection of pancreatic cancer. For many, this test signifies hope in a disease that has not provided much hope to people for a long time.
We're celebrating the Fourth of July with “Grillin with Dad” Maciek Zurawski. He's firing up the smoker for a patriotic, easy-to-prepare flat iron steak.
Today’s skilled job seeker demands a workplace and business culture that not only offers solid income, but one rich in experience, diversity, equity, and inclusion. A perfect example: Baring.
Quality higher education is more convenient, more accessible and more affordable than ever. Learn more now.